Methods for assessing response to inflammatory disease therapy withdrawal

A method for treating a subject having an arthritic disorder, the method comprising:

• a) administering a therapeutic regimen to the subject until the subject reaches a clinically low level or remission level of disease activity, the therapeutic regimen comprising one or more of DMARD therapy, reversible bariatric surgery, and administration of a therapeutic compound;
• b) performing an immunoassay on a sample from the subject to generate a score based on a set of quantitative data, wherein the set of quantitative data comprises expression data for a set of biomarkers comprising chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1);
• C-reactive protein, pentraxin-related (CRP);
• epidermal growth factor (beta-urogastrone) (EGF);
• interleukin 6 (interferon, beta 2) (IL6);
• leptin (LEP);
• matrix metallopeptidase 1 (interstitial collagenase) (MMP1);
• matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3);
• resistin (RETN);
• serum amyloid A1 (SAA1);
• tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A);
• vascular cell adhesion molecule 1 (VCAM1);
• and, vascular endothelial growth factor A (VEGFA);
• c) determining from the score that the subject has an increased risk of relapse;
• and
• d) continuing the therapeutic regimen or restarting the therapeutic regimen before the occurrence of relapse.